Table 2 Characteristics of the 111 nodules
From: Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features
Characteristic | Value (%) |
|---|---|
Diameter of largest nodule | |
< 5 cm | 85 (76.6) |
≥ 5 cm | 26 (23.4) |
HCCs per patient | |
1 | 53 (47.7) |
≥ 2 | 58 (52.3) |
Nodule location in the liver | |
Right liver | 81 (73.0) |
Median liver | 13 (11.7) |
Left liver | 17 (15.3) |
Irregular margin | |
Smooth | 48 (43.2) |
Irregular | 63 (56.8) |
Arterial peritumoral enhancement | |
Absent | 100 (90.1) |
Present | 11 (9.9) |
Satellite nodules | |
Absent | 91 (82.0) |
Present | 20 (18.0) |
Peripheral lesion | |
Absent | 22 (19.8) |
Present | 89 (80.2) |
Nonrim arterial phase hyperenhancement | |
Absent | 3 (2.7) |
Present | 108 (97.3) |
Nonperipheral washout | |
Absent | 11 (9.9) |
Present | 100 (90.1) |
Radiological capsule | |
Absent | 21 (18.9) |
Present | 90 (81.1) |
Fat in mass | |
Absent | 76 (68.5) |
Present | 35 (31.5) |
Blood products in mass | |
Absent | 84 (75.7) |
Present | 27 (24.3) |
Nodule-in-nodule | |
Absent | 105 (94.6) |
Present | 6 (5.4) |
Mosaic architecture | |
Absent | 49 (44.1) |
Present | 62 (55.9) |
Restricted diffusion | |
Absent | 12 (10.8) |
Present | 99 (89.2) |
Mild-to-moderate T2 hyperintensity | |
Absent | 11 (9.9) |
Present | 100 (90.1) |